H-1B Filings
36
DOL labor condition applications on file
GlaxoSmithKline LLC in PA (Manufacturing) shows all three federal tracks on this profile: 36 H-1B LCAs, an employer OSHA injury record, and 1 WARN notice.
GlaxoSmithKline LLC (PA): · 36 H-1B LCAs at a $138,570 disclosed median · OSHA Grade A (DART 0.30) · 1 WARN notice
According to DOL OFLC H-1B disclosures, OSHA ITA injury logs, and state WARN Act notices, GlaxoSmithKline LLC in PA carries 36 H-1B wage filings on record, a $138,570 median wage across 35 disclosed-wage positions (above the $120,000 national median), a strong A OSHA safety grade and 1 WARN layoff notice on file. H-1B filing volume ranks #744 of 36,919 sponsors in this corpus (about the 98th percentile). Every figure is a federal filing, not an estimate; see methodology for coverage limits.
Layoff & federal record
According to U.S. Department of Labor, OSHA, and state WARN Act filings, GlaxoSmithKline LLC carries 36 H-1B wage filings on record, a $138,570 median wage across 35 disclosed-wage positions (above the $120,000 national median), a strong A OSHA safety grade and 1 WARN layoff notice on file. In this corpus, H-1B filing volume ranks #744 of 36,919 sponsors in this corpus (about the 98th percentile), and disclosed median wage sits at the 64th percentile of 178,031 credible H-1B wage rows.
Figures above come from DOL H-1B LCAs, this employer's OSHA injury log, and state WARN notices, three independent disclosure systems.
DOL LCA release change
H-1B Filings
36
DOL labor condition applications on file
Median H-1B Salary
$138,570
Across 35 disclosed positions
OSHA Safety Grade
Grade A · DART 0.30
vs 1.14 same 2-digit NAICS sector (OSHA ITA 2022–2023, hours-weighted)
WARN Workforce Impact
150 workers
1 WARN Act notice on file
Where GlaxoSmithKline LLC's H-1B wage sits nationally
Median disclosed wage vs. all US employers with H-1B filings
$138,570 Top 36% higher than 64% of 178,031 US employers
Each bar is a $20K-wide band; taller bars hold more US employers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source DOL Office of Foreign Labor Certification, H-1B Disclosure Data · August 2026
Filing-count-weighted median across this employer's own disclosed H-1B positions (-4% year over year), not a company-wide raise, and not adjusted for role mix changes between years.
| Field | Value | Source |
|---|---|---|
| Employer Name | GlaxoSmithKline LLC | DOL OFLC / OSHA / WARN |
| Industry | Manufacturing | NAICS / DOL |
| State | PA | U.S. Federal Records |
| H-1B Filings | 36 | DOL OFLC LCA Disclosure |
| H-1B Median Salary | $138,570 | DOL OFLC LCA Disclosure |
| OSHA Safety Grade | A | OSHA ITA |
| OSHA DART Rate | 0.30 | OSHA ITA Establishment Records |
| WARN Layoff Notices | 1 notice(s), 150 workers | WARN Act notices, state workforce agency originals (archival backstop: LayoffData.com) |
GlaxoSmithKline LLC's values above reflect the most recent DOL Labor Condition Applications, OSHA Injury Tracking Application records, WARN Act notices on file for this employer in PA (Manufacturing). In this corpus, H-1B filing volume ranks #744 of 36,919 sponsors in this corpus (about the 98th percentile); disclosed median wage sits at the 64th percentile of 178,031 credible H-1B wage rows; OSHA DART rate is safer than roughly 97% of 135,691 employers with an establishment injury record.
| Job Title | Median |
|---|---|
| Executive Director Precision Medicine Portfolio Planning | $273,700 |
| Senior Director of Engineering | $205,700 |
| Senior Platform Engineer - Governance | $182,312 |
| Director - Quantitative Systems Pharmacology | $180,750 |
| Senior Application Engineer | $172,744 |
| Scientific Director, Immunoassays | $161,857 |
| Senior Product Manager - Compute Platform | $159,885 |
| Assoc. Director, Machine Learning Developer & Data Scientist | $158,000 |
| Manager Business Analytics | $153,733 |
| Manager Business Analytics | $153,733 |
| Quality R&D Operations Drug Product Director | $152,574 |
| Manager Medical Analytics Insights | $151,523 |
| Cloud Engineer II | $147,846 |
| Specialty Analytics Manager | $145,687 |
| Principal Tech Product Owner: Oncology Development | $142,771 |
| Investigator | $142,120 |
| Associate Director and Group Leader, LC-MS BESM | $141,083 |
| Digital Marketing Tech, Senior Architect | $138,570 |
| Sr Manager - Oncology Commercial Analytics, Multiple Myeloma | $136,323 |
| Associate Director - Genomic Technologies, HGG | $133,500 |
| Clinical Research Statistician | $127,965 |
| Investigator - Biomarkers, Oncology | $122,853 |
| Investigator, Modeling & Simulation | $120,411 |
| Forecasting Manager | $119,250 |
| Assistant General Counsel, Legal “ Business Development | $117,645 |
| Scientific Investigator | $111,350 |
| Scientific Investigator | $111,350 |
| Scientific Investigator - Genome Biology, TD | $111,350 |
| Scientific Investigator - Omics Sciences, TD | $110,424 |
| Investigator, Modeling and Simulation | $110,250 |
| Principal Scientist, Discovery Bioanalysis | $109,616 |
| Principal Scientist, Discovery DMPK Bioanalyst, US | $109,616 |
| Programmer Analyst | $105,494 |
| Senior Scientist | $89,058 |
| Supply Chain Planner | $88,500 |
GlaxoSmithKline LLC operating in PA within the Manufacturing sector: the company has filed 36 H-1B labor condition applications, of which 35 disclose a usable wage figure with a median of $138,570. Records here combine U.S. Department of Labor disclosures and state workforce agency filings.
On workplace safety, GlaxoSmithKline LLC posted a DART (Days Away, Restricted, Transferred) rate of 0.30 injuries per 100 full-time workers, compared with the hours-weighted average of 1.14 for the same 2-digit NAICS sector in OSHA ITA 2022–2023 filings. Our composite grade of "A" is that employer-to-sector ratio (A ≤0.5× sector · B ≤0.8× · C ≤1.2× · D ≤1.8× · else F), so a job seeker can compare a hospital chain to a warehouse or a bank to a food processor without chasing down OSHA formulas. Across all years on file, OSHA logged 15 reportable injuries at this employer.
1 WARN Act notice affecting 150 workers has been filed against GlaxoSmithKline LLC in PA. Multiple notices can mean consolidations or broader restructuring; weigh them next to this employer's pay and safety signals, and the employer's own disclosures, when judging an offer.
GlaxoSmithKline LLC is one of the rarer profiles that carries both sponsorship volume (36 H-1B LCAs) and WARN history (1 notice) in the same public record for Manufacturing in PA. Weigh those two signals separately before treating either as the whole story.
GlaxoSmithKline LLC's DART rate (days away/restricted/transferred per 100 FTE) vs the hours-weighted 2-digit NAICS sector average from OSHA ITA 2022–2023 (Manufacturing).
Total reported injuries on file: 15.
GlaxoSmithKline LLC's nearest H-1B-filing peers in Manufacturing (home state PA). Each card links to that employer's federal-records profile.
| Notice Date | Workers |
|---|---|
| 2015-02-01 | 150 |
What to check before working with GlaxoSmithKline LLC
GlaxoSmithKline LLC needs a three-way read: H-1B pay (36 LCAs), safety (grade A), and WARN history (1 notice); none of those alone is the rating.
GlaxoSmithKline LLC's figures are legally filed public records (DOL, OSHA, state WARN), not reviews or vendor estimates; a missing row is not proof the underlying activity never happened.
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from OSHA and the DOL Wage and Hour Division. Consult a qualified professional before making decisions based on this data.
Learn more: Safety Grades Explained | H-1B Salary Negotiation
Read our methodology - how this data is sourced, computed, and verified.
This profile is rendered directly from DOL H-1B disclosure filings, OSHA Injury Tracking Application records and state WARN Act layoff notices, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.